Burris HA - Search Results

1

Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies.

Villalona-Calero MA, Weiss GR, Burris HA, Kraynak M, Rodrigues G, Drengler RL, Eckhardt SG, Reigner B, Moczygemba J, Burger HU, Griffin T, Von Hoff DD, Rowinsky EK. Villalona-Calero MA, et al. Among authors: burris ha. J Clin Oncol. 1999 Jun;17(6):1915-25. doi: 10.1200/JCO.1999.17.6.1915. J Clin Oncol. 1999. PMID: 10561233 Clinical Trial.

2

A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days.

Wall JG, Burris HA 3rd, Von Hoff DD, Rodriguez G, Kneuper-Hall R, Shaffer D, O'Rourke T, Brown T, Weiss G, Clark G, et al. Wall JG, et al. Among authors: burris ha 3rd. Anticancer Drugs. 1992 Aug;3(4):337-45. doi: 10.1097/00001813-199208000-00004. Anticancer Drugs. 1992. PMID: 1330081 Clinical Trial.

3

Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro.

Burris HA 3rd, Hanauske AR, Johnson RK, Marshall MH, Kuhn JG, Hilsenbeck SG, Von Hoff DD. Burris HA 3rd, et al. J Natl Cancer Inst. 1992 Dec 2;84(23):1816-20. doi: 10.1093/jnci/84.23.1816. J Natl Cancer Inst. 1992. PMID: 1331485

4

Clinical trials with the topoisomerase I inhibitors.

Burris HA, Rothenberg ML, Kuhn JG, Von Hoff DD. Burris HA, et al. Semin Oncol. 1992 Dec;19(6):663-9. Semin Oncol. 1992. PMID: 1334279 Review.

5

New anticancer agents.

Brown TD, Burris HA, Eckardt JR, O'Rourke TJ, Rodriguez GI, Wall JG, Weiss GR. Brown TD, et al. Among authors: burris ha. Cancer Chemother Biol Response Modif. 1992;13:115-55. Cancer Chemother Biol Response Modif. 1992. PMID: 1389907 Review. No abstract available.

6

Preclinical leads for innovative uses for etoposide.

Von Hoff DD, McGill J, Davidson K, Forseth B, Atef Ebrahim el-Zayat A, Burris H. Von Hoff DD, et al. Semin Oncol. 1992 Dec;19(6 Suppl 13):10-3. Semin Oncol. 1992. PMID: 1492222

7

Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.

Rinaldi DA, Burris HA, Dorr FA, Woodworth JR, Kuhn JG, Eckardt JR, Rodriguez G, Corso SW, Fields SM, Langley C, et al. Rinaldi DA, et al. Among authors: burris ha. J Clin Oncol. 1995 Nov;13(11):2842-50. doi: 10.1200/JCO.1995.13.11.2842. J Clin Oncol. 1995. PMID: 7595747 Clinical Trial.

8

Phase IA/IB evaluation of mammalian cell-derived glycosylated recombinant human interleukin (SIGOSIX) before and after cytotoxic chemotherapy.

Ritch PS, Keever C, Schiller J, Rivkin S, Witt PL, Grossberg SE, Truitt RL, Burris H, von Hoff DD, Vaickus L, et al. Ritch PS, et al. Ann N Y Acad Sci. 1995 Jul 21;762:359-60. doi: 10.1111/j.1749-6632.1995.tb32340.x. Ann N Y Acad Sci. 1995. PMID: 7668536 Clinical Trial. No abstract available.

9

New anticancer agents.

Weiss GR, Burris HA 3rd, Eckardt JR, Fields S, O'Rourke T, Rodriguez GI, Rothenberg ML. Weiss GR, et al. Among authors: burris ha 3rd. Cancer Chemother Biol Response Modif. 1994;15:130-51. Cancer Chemother Biol Response Modif. 1994. PMID: 7779583 Review. No abstract available.

10

A phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors.

Weiss GR, Kuhn JG, Rizzo J, Smith LS, Rodriguez GI, Eckardt JR, Burris HA 3rd, Fields S, VanDenBerg K, von Hoff DD. Weiss GR, et al. Among authors: burris ha 3rd. Cancer Chemother Pharmacol. 1995;35(5):397-402. doi: 10.1007/s002800050253. Cancer Chemother Pharmacol. 1995. PMID: 7850921 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

432 results

Search Page